Correction: Effectiveness and safety of subcutaneous immunotherapy using a depigmented, polymerized extract of cat epithelium in allergic patients: a retrospective, real-world study

There was a mistake in Figure 1 as published. The image for Figure 1 was inadvertently swapped with Figure 2. The captions were correct.

The correct Figure 1 and its caption appears below:

Figure 1. Percentage of patients with different severity of rhinitis (left panel) and asthma (right panel) symptoms at baseline and after 24 months of allergen-specific immunotherapy. Symptom severity is color-coded as shown in the box at the bottom right of the figure.

The corrected Figure 2 and its caption appears below:

Figure 2. Evolution of the percentage of patients without nasal, ocular and bronchial symptoms at baseline and after 6 months, 12 months and LOCF (Last Observation Carried Forward) of allergen-specific immunotherapy. Percentages are shown above each histogram bar. Symptoms are color-coded as shown in the box at the bottom right of the figure.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland